Key facts
- It has raised $3.0M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Sep 2025.
- Notable investors include Springboard Enterprises, Lung, National Heart, Penn Center for Innovation, University of Pennsylvania — 6 tracked in total.
- Prolifagen has filed 1 Form D with the SEC, most recently Sep 2025 ($3.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Prolifagen
Funding rounds
2 roundsAbout Prolifagen
Developer of ribonucleic acid therapeutics technology designed for cardiac tissue regeneration following myocardial injury. The company's technology transiently induces proliferation of adult cardiomyocytes through the delivery of a microRNA compound targeting the Hippo signaling pathway, enabling the cardiovascular therapeutics sector to address post-infarct cardiac dysfunction by promoting regeneration of functional heart muscle and reducing progression to heart failure.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Doylestown, PA, United States
- Founded
- 2016
- Employees
- 5
- Website
- prolifagen.com/
- Ownership
- Privately Held (backing)
Prolifagen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prolifagen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prolifagen in its N-PORT filings yet. We sweep new filings monthly.